Eye Gene consortium begins first-phase clinical trial dosing of COVID-19 mRNA vaccine
Predicted impact: Medium
Phase 1 dosing start for a small biotech; meaningful milestone, size unknown.
Eye Gene아이진
185490 · KOSDAQ · ₩185490 · 아이진
₩1,705▼ ₩45 (2.57%)End-of-day · Oct 30, 2026 · End-of-day prices.
Ajinbio to Build Eye-Snow Avastin-Style Plant? iGeneTec Enters Phase 1/2a Trials Next Year
Predicted impact: Medium
Plans for plant and phase 1/2a trial next year; early-stage, small company with revenue of KRW 4.5 billion.
Also known as: Eye Gene / 아이진 / 185490 / KRX:185490
Source: KRX statistical information